Claudia Benedetti

Dr. Claudia Benedetti

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SHSusan Hartzell
Susan Hartzell
SBSofia Bin
Sofia Bin
CBClaudia Benedetti
Claudia Benedetti
MHMeredith Haverly
Meredith Haverly
LGLorenzo Gallon
Lorenzo Gallon
Paolo CravediPaolo Cravedi
Paolo Cravedi
Whether kidney transplant recipients are capable of mounting an effective anti‐SARS‐CoV‐2 adaptive immune response despite chronic immunosuppression is unknown and has important implications for therapy. Herein, we analyzed peripheral blood cell surface and intracellular cytokine phenotyping by flow cytometry along with serum antibody testing in 18 kidney transplant recipients with active COVID‐19 infection and 36 matched, transplanted controls without COVID‐19. We observed significantly fewer total lymphocytes, fewer circulating memory CD4+ and CD8+ T cells in the COVID‐19 subjects. We also showed fewer anergic and senescent CD8+ T cells in COVID‐19 individuals, but no differences in exhausted CD8+ T cells, nor in any of these CD4+ T cell subsets between groups. We also observed greater frequencies of activated B cells in the COVID‐19 patients. Sixteen of 18 COVID‐19 subjects tested for anti‐SARS‐CoV‐2 serum antibodies showed positive IgM or IgG titers. Additional analyses showed no significant correlation s among immune phenotypes and degrees of COVID‐19 disease severity. Our findings indicate that immunosuppressed kidney transplant recipients admitted to the hospital with acute COVID‐19 infection can mount SARS‐CoV‐2‐reactive adaptive immune responses. The findings raise the possibility that empiric reductions in immunosuppressive therapy for all kidney transplant recipients with active COVID‐19 may not be required.

24 October 2022 in Cardiorenal Medicine
Verified
Journal Article
Open access
PDF file
PLPaolo Lentini
Paolo Lentini
LZLuca Zanoli
Luca Zanoli
CRClaudio Ronco
Claudio Ronco
CBClaudia Benedetti
Claudia Benedetti
APAntonino Previti
Antonino Previti
GGGiovanni Gambaro
Giovanni Gambaro
Background: The incidence of cardiovascular disease (CVD) is increased in patients with diabetic kidney disease (DKD). Summary: Aortic stiffness is a well-accepted biomarker for cardiovascular (CV) events in all stages of CKD. The worldwide prevalence of diabetes continues to grow, as does the prevalence of DKD. Insulin resistance, hyperglycaemia, hypertension, and the metabolic abnormalities of type-2 diabetes are all involved in the pathogenesis of CVD. The effect of these toxins on cardiac and vascular function is amplified by the worsening of renal function and the parallel rise of uraemic toxins. Key Messages: In this narrative review, we analysed why arterial stiffening can be considered a vascular mediator between diabetes and cardiac dysfunction, and we discussed the strong CV and nephroprotective effects of sodium-glucose cotransporter type-2 inhibitors.

Verified
Journal Article
Open access
PDF file
MMMatteo Marcello
Matteo Marcello
MSMarco Simonini
Marco Simonini
ALAnna Lorenzin
Anna Lorenzin
VCValentina Corradi
Valentina Corradi
Grazia Maria VirzìGrazia Maria Virzì
Grazia Maria Virzì
CRClaudio Ronco
Claudio Ronco
Background: Removal of large uraemic toxins is still a challenge. Haemodiafiltration (HDF) has produced some results, although large convective volume, optimal vascular access to increase the blood flow rate and strict water quality management are required. Medium cut-off, high-retention-onset membranes have been recently developed, introducing the concept therapy called expanded haemodialysis (HDx). Furthermore, vitamin E-coated membrane has potential beneficial effects on inflammation and oxidative stress. Methods: A prospective longitudinal multicentre study was conducted for 3 months among 24 chronic haemodialysis patients. Patients were randomly assigned into either HDF with high-flux membrane or HDx with Theranova or ViE-X membrane. The primary goal was to assess albumin loss among the three types of dialyzers. Secondary goals included assessment of depurative efficacy for uraemic toxins and clinical outcomes. Results: Mean albumin loss was significantly higher in patients undergoing HDx with Theranova membrane, without any difference in serum albumin concentration among the three groups. Instantaneous clearance of small and middle molecules was significantly higher in patients undergoing HDF, but we did not find differences in removal ratio and Kt/V. Reduction in the erythropoietin resistance index was observed in patients treated with ViE-X membrane due to their lower dialysis vintage. Conclusions: The higher albumin loss during HDx has no effects on pre-dialysis serum albumin. HDx with Theranova in the presence of lower session length, lower Qb, lower convective dose, and lower instantaneous clearance reached the same dialysis efficacy compared to HDF.

20 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMatteo Marcello
Matteo Marcello
MSMarco Simonini
Marco Simonini
ALAnna Lorenzin
Anna Lorenzin
VCValentina Corradi
Valentina Corradi
GVGrazia Maria Virzi
Grazia Maria Virzi
CRClaudio Ronco
Claudio Ronco
Background: Removal of large uraemic toxins is still a challenge. HDF has produced some results although large convective volume, optimal vascular access to increase the blood flow rate and strict water quality management are required. Medium Cut-Off, high Retention Onset membrane have been recently developed introducing the concept therapy called “expanded haemodialysis” (HDx). Furthermore, vitamin E-coated membrane has potential beneficial effects on inflammation and oxidative stress. Ma-terial and Methods: A prospective longitudinal multi-center study was conducted for 3 months among 24 chronic haemodialysis patients. Patients were randomly assigned into either HDF with high flux membrane or HDx with Theranova or ViE-X mem-brane. The primary goal was to assess albumin loss among the three types of dialyzers. Secondary goals included assessment of depurative efficacy for uraemic toxins and clinical outcomes. Results: Mean albumin loss was significantly higher in patients undergoing HDx with Theranova membrane (ANOVA, p< 0.001) without any differ-ence in serum albumin concentration among the three groups. Instantaneous clearance of small and middle molecules was significantly higher in patients undergoing HDF, but we didn’t find differences in removal ratio and Kt/V. Reduction of Erythropoietin resistance index was observed in patients treated with ViE-X membrane due to their lower dialysis vintage. Conclusion: The higher albumin loss during HDx has no effects on pre-dialysis serum albumin. HDx with Theranova® in presence of lower session length, lower Qb , lower convective dose and lower instantaneous clearance reached same dialysis efficacy compared to HDF.